Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Vipoma 1Somatostatinoma 1Insulinoma 1Glucagonoma 1Gliosarcoma 1Glioblastoma 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Islet Cell 1

Interventions

Radiotherapy 15Temozolomide 14Carmustine 6Lomustine 3Chemotherapy, Adjuvant 3Bevacizumab 3imetelstat 2Radiosurgery 2Radiation 2Immunohistochemistry 2Everolimus 2DNA Methylation 2vistusertib 1veliparib 1vatalanib 1temsirolimus 1sagopilone 1rubitecan 1palbociclib 1mercaptoundecahydrododecaborate 1marizomib 1lonafarnib 1fluciclovine F-18 1carmustine, poliferprosan 20 drug combination 1beta-D-glucosylisophosphoramide mustard 1azurin (50-77) 1Tamoxifen 1Re-Irradiation 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Glioblastoma × vatalanib × Clear all
NCT00128700 2012-09-24

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1/2 Completed
20 enrolled
CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡